ATE399768T1 - Indazolderivate und ihre verwendung als crf antagonisten - Google Patents

Indazolderivate und ihre verwendung als crf antagonisten

Info

Publication number
ATE399768T1
ATE399768T1 AT03776916T AT03776916T ATE399768T1 AT E399768 T1 ATE399768 T1 AT E399768T1 AT 03776916 T AT03776916 T AT 03776916T AT 03776916 T AT03776916 T AT 03776916T AT E399768 T1 ATE399768 T1 AT E399768T1
Authority
AT
Austria
Prior art keywords
crf antagonists
indazol
derivatives
indazol derivatives
crf
Prior art date
Application number
AT03776916T
Other languages
English (en)
Inventor
Richard Cournoyer
David Loughhead
Counde O'yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE399768T1 publication Critical patent/ATE399768T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03776916T 2002-12-02 2003-11-24 Indazolderivate und ihre verwendung als crf antagonisten ATE399768T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43016802P 2002-12-02 2002-12-02

Publications (1)

Publication Number Publication Date
ATE399768T1 true ATE399768T1 (de) 2008-07-15

Family

ID=32469420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03776916T ATE399768T1 (de) 2002-12-02 2003-11-24 Indazolderivate und ihre verwendung als crf antagonisten

Country Status (21)

Country Link
US (2) US7214699B2 (de)
EP (1) EP1569911B1 (de)
JP (1) JP4401298B2 (de)
KR (1) KR100761562B1 (de)
CN (1) CN100439341C (de)
AR (1) AR042148A1 (de)
AT (1) ATE399768T1 (de)
AU (1) AU2003286180B2 (de)
BR (1) BR0316950A (de)
CA (1) CA2507074A1 (de)
DE (1) DE60321958D1 (de)
ES (1) ES2309368T3 (de)
GT (1) GT200300263A (de)
MX (1) MXPA05005794A (de)
PA (1) PA8589601A1 (de)
PE (1) PE20040764A1 (de)
PL (1) PL377609A1 (de)
RU (1) RU2341518C2 (de)
TW (1) TW200418816A (de)
UY (1) UY28105A1 (de)
WO (1) WO2004050634A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR100742014B1 (ko) * 2003-08-14 2007-07-23 에프. 호프만-라 로슈 아게 Gaba계 조절제
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
PE20060373A1 (es) * 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
WO2006017384A2 (en) 2004-08-03 2006-02-16 Wyeth Indazoles useful in treating cardiovascular diseases
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
EP2007753B1 (de) * 2006-04-11 2009-11-11 F. Hoffmann-Roche AG Heterocyclische modulatoren für den gaba-alpha-subtyp-selektiven rezeptor
ITMI20062230A1 (it) * 2006-11-22 2008-05-23 Acraf Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US8273900B2 (en) * 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2012026511A1 (ja) * 2010-08-27 2012-03-01 協和発酵キリン株式会社 医薬組成物
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6490215B2 (ja) * 2014-07-24 2019-03-27 ベータ ファーマ,インコーポレイテッド サイクリン依存性キナーゼ(cdk)阻害剤としての2−h−インダゾール誘導体およびその治療上の使用
KR101713303B1 (ko) * 2015-12-24 2017-03-07 강원대학교산학협력단 2h-인다졸 유도체의 제조방법
WO2022107064A1 (en) 2020-11-20 2022-05-27 Idemitsu Kosan Co., Ltd. Heterocyclic compound and an organic electroluminescence device comprising the heterocyclic compound
CN113831319A (zh) * 2021-10-19 2021-12-24 北京科技大学 含有大位阻取代基芳基硼酸/硼酸酯的铃木反应方法
KR20230081778A (ko) 2021-11-29 2023-06-08 조이운 VOCs 저감장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005109A (en) * 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
PL175831B1 (pl) * 1992-12-17 1999-02-26 Pfizer Pochodna pirazolu
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5705646A (en) * 1993-09-30 1998-01-06 Pfizer Inc. Substituted pyrazoles as CRF antagonists
US5668145A (en) * 1993-11-12 1997-09-16 Pfizer Inc. Amino-substituted pyrazoles having CRF antagonistic activity
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
US5760225A (en) * 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
NZ503918A (en) 1997-11-04 2002-03-28 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
AU2001234958A1 (en) * 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
AU2001267852B2 (en) * 2000-06-30 2006-01-19 Msd K.K. Novel pyrazinone derivatives
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2002016348A1 (en) * 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
BR0212613A (pt) * 2001-09-19 2004-08-31 Pharmacia Corp Compostos de indazol substituìdos para o tratamento de inflamação
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
TW200409759A (en) * 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols

Also Published As

Publication number Publication date
KR100761562B1 (ko) 2007-10-04
AU2003286180B2 (en) 2009-11-12
BR0316950A (pt) 2006-01-17
CN1732158A (zh) 2006-02-08
RU2005120770A (ru) 2006-02-10
UY28105A1 (es) 2004-05-31
RU2341518C2 (ru) 2008-12-20
MXPA05005794A (es) 2005-08-16
EP1569911B1 (de) 2008-07-02
CA2507074A1 (en) 2004-06-17
EP1569911A1 (de) 2005-09-07
PA8589601A1 (es) 2004-09-16
US7214699B2 (en) 2007-05-08
TW200418816A (en) 2004-10-01
ES2309368T3 (es) 2008-12-16
CN100439341C (zh) 2008-12-03
JP2006510625A (ja) 2006-03-30
JP4401298B2 (ja) 2010-01-20
PL377609A1 (pl) 2006-02-06
PE20040764A1 (es) 2004-11-06
DE60321958D1 (de) 2008-08-14
KR20050084079A (ko) 2005-08-26
AR042148A1 (es) 2005-06-08
GT200300263A (es) 2004-06-28
WO2004050634A1 (en) 2004-06-17
AU2003286180A1 (en) 2004-06-23
US20040110815A1 (en) 2004-06-10
US20070213373A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
ATE399768T1 (de) Indazolderivate und ihre verwendung als crf antagonisten
ATE371658T1 (de) Purinderivate und ihre verwendung als liganden des cannabinoid rezeptors
DE60314600D1 (de) O-cyclopropyl-carboxanilide und ihre verwendung als fungizide
DE60308387D1 (de) Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
DE60317093D1 (de) Chinolin-; isochinolin- und chinazolinoxyalkylamide und ihre verwendung als fungizide
DE60309874D1 (de) Malonsäuerenitril-verbindungen und ihre verwendung als pestizide
DE60234167D1 (de) Bipiperidin-derivate und ihre verwendung als inhibitoren der chemokinrezeptoren
ATE521598T1 (de) 5-phenylthiazol-derivate und ihre verwendung als pi3 kinase inhibitoren
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DE60332396D1 (de) PYRAZOLOi3,4-B PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PHOSPHODIESTERASE INHIBITOREN
DE60123210D1 (de) Picolinsäure-derivate und ihre verwendung als fungizide
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60321558D1 (de) Chinolinderivate und deren verwendung als 5-ht6 liganden
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
ATE430729T1 (de) Pyrrol- und pyrazolderivate als potentiatoren von glutamatrezeptoren
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
ATE438395T1 (de) Pyrazolderivate und ihre verwendung als orexin- rezeptor-antagonisten
ATE329906T1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
DE602004010426D1 (de) Mikrobizide zusammensetzungen und ihre verwendung
DE50313157D1 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
ATE551329T1 (de) Chinazolinonderivate und deren verwendung als cb- agonisten
ATE531259T1 (de) 2-alkyl-cycloalk(en)yl-carboxamide und ihre verwendung als fungizide
ATE384054T1 (de) Substituierte benzoxazinones und ihre verwendung
ATE427748T1 (de) Pyridin-derivate und ihre verwendung als urotensin ii antagonisten
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1569911

Country of ref document: EP

REN Ceased due to non-payment of the annual fee